Medtronic Launches Obesity Division With $260 Mil. Transneuronix Purchase
This article was originally published in The Gray Sheet
Executive Summary
Transneuronix' Transcend gastric electrical stimulation device is the first product scheduled for commercialization by Medtronic's obesity management division
You may also be interested in...
EnteroMedics Maestro Obesity Management Implant PMA Slated For 2008
EnteroMedics expects to file an investigational device exemption with FDA by year end for U.S. trials of its Maestro obesity management implant
EnteroMedics Maestro Obesity Management Implant PMA Slated For 2008
EnteroMedics expects to file an investigational device exemption with FDA by year end for U.S. trials of its Maestro obesity management implant
Medtronic in poor SHAPE
Preliminary results of the firm's Screened Health Assessment and Pacer Evaluation trial randomizing patients who received implantable gastric stimulation therapy for the management of obesity against a placebo group failed to meet the efficacy endpoint of a 10 percentage-point difference in mean excess weight loss at one year, the firm announces Dec. 8. Medtronic says it is still committed to the technology and believes the SHAPE trial was influenced by unplanned treatment changes. The trial was initiated in May 2004 by Transneuronix, which Medtronic acquired in July 2005 (1"The Gray Sheet" July 4, 2005, p. 10)...